AKL Research & Development Ltd is a UK-based pharmaceutical company that develops novel therapeutics for inflammatory diseases such as osteoarthritis, Alzheimer's, rheumatoid arthritis, and scleroderma. The company seeks inspiration from nature to combat some of the biggest challenges facing modern medicine today. They identify secondary metabolites of plant origin with proven efficacy and safety, which are then synthesized and undergo standard pharmaceutical clinical development. AKL's innovative approach greatly increases the chances of success while reducing the risk of side effects. The company is currently conducting formal human clinical trials of an investigational oral therapy called APPA for the treatment of osteoarthritis, a common and devastating disease with limited treatment options and no cure. APPA is also being evaluated for other inflammatory diseases, and other molecules are under investigation. AKL Research & Development Ltd, trading as AKL Therapeutics Ltd, welcomes enquiries from potential investors and partners as they continue the development and commercialisation process.